Related Experiment Videos
[Low-dose intermittent intra-arterial infusion chemotherapy]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1985
Summary
Low dose-intermittent intraarterial chemotherapy offers an effective and safer approach for regional cancers, including liver metastases. This method improves drug delivery to the liver, leading to tolerable side effects and extended hospital-free intervals for patients.
Area of Science:
- Oncology
- Pharmacology
- Medical Technology
Background:
- Arterial infusion chemotherapy is a key treatment for localized cancers.
- A novel method for intra-hepatic arterial catheterization via the left subclavian artery with a silicone reservoir was previously established.
- This study evaluates low dose-intermittent intraarterial (i.a.) infusion chemotherapy.
Observation:
- 70 patients with liver metastases, primary hepatocellular carcinoma, or other GI malignancies were treated from February 1982.
- Treatment regimens included varying doses of MMC, 5-FU, AraC, and ADM.
- Pharmacokinetic studies using 99mTc-RBC showed a 10.0 ratio of i.a. to i.v. drug delivery to the liver.
Findings:
- Partial response rates were 43% (21/49) with an average hospital-free interval of 156 days.
- Side effects were limited to mild bone marrow suppression and anorexia, manageable in outpatient settings.
- The enhanced liver drug delivery ratio supports the efficacy of low-dose intraarterial anti-tumor agents.
Implications:
- Low dose-intermittent i.a. infusion chemotherapy is a viable and safe option for induction and maintenance therapy in regionally located cancers.
- This approach enhances local drug concentration, potentially improving treatment outcomes.
- The findings suggest intraarterial chemotherapy is a beneficial modality for managing liver malignancies and other regional cancers.